Evaluation of the Clearview Clostridium difficile Toxin A Test and various selective culture media in comparison with the cytotoxin assay for the diagnosis of Clostridium difficile-associated diarrhoea

被引:7
|
作者
Anderson, TL [1 ]
McGregor, A [1 ]
机构
[1] Royal Hobart Hosp, Dept Microbiol & Infect Dis, Hobart, Tas 7000, Australia
关键词
Clostridium difficile; nosocomial diarrhoea; toxin A EIA; culture; tissue culture cytotoxin assay;
D O I
10.1080/0031302031000123236
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Aim: Clostridium difficile is the major pathogen associated with nosocomial diarrhoea. We evaluated the performances of a commercially available toxin A enzyme immunoassay (EIA; Clearview C. difficile Toxin A Test), culture and tissue culture cytotoxin assay in the diagnosis of C. difficile-associated diarrhoea. Methods: Comparative test performance was determined from data obtained from 166 faecal samples. The initial analysis compared the performance of toxin A EIA and culture with that of cytotoxin assay, this being defined as a 'laboratory gold standard'. A second analysis compared the individual performance of the toxin A EIA, culture and cytotoxin assay using a combined clinical and laboratory diagnostic assessment as a 'clinical gold standard'. In a parallel, study three selective culture media were compared. Results: From the initial analysis, the sensitivity and specificity of the methods were, respectively, 84.6 and 65.4% for the toxin A EIA, and 38.5 and 93.5% for culture. From the second analysis, the sensitivity and specificity of the methods were, respectively, 100 and 67.5% for the toxin A EIA, 63.6 and 96.7% for culture and 72.7 and 98.0% for cytotoxin assay. Media containing d-cycloserine 250 mg/L and cefoxitin 8 mg/L performed best, growing 88.2% of the isolates. Conclusion: The toxin A EIA we evaluated had poor specificity in the diagnosis of C. difficile-associated diarrhoea. We conclude that in our laboratory the combination of culture and cytotoxin assay is a preferred approach to the diagnosis of C. difficile-associated diarrhoea.
引用
收藏
页码:244 / 247
页数:4
相关论文
共 50 条
  • [2] Clostridium difficile-associated diarrhoea
    Elliott, B.
    Chang, B. J.
    Golledge, C. L.
    Riley, T. V.
    INTERNAL MEDICINE JOURNAL, 2007, 37 (08) : 561 - 568
  • [3] Clostridium difficile-associated diarrhoea
    Wight, N
    Curtis, H
    Hyde, J
    Borriello, SP
    Mahida, YR
    POSTGRADUATE MEDICAL JOURNAL, 1998, 74 (877) : 677 - 678
  • [5] Pathogenesis of Clostridium difficile-associated diarrhoea
    Pothoulakis, C
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1996, 8 (11) : 1041 - 1047
  • [6] Laboratory diagnosis of Clostridium difficile-associated diarrhoea: microbiologists (should) do it with culture
    Jaksic, A. Sasha
    Nimmo, Graeme R.
    Dwyer, Brian W.
    PATHOLOGY, 2009, 41 (02) : 187 - 188
  • [7] Fidaxomicin in the Treatment of Clostridium difficile-Associated Diarrhoea
    Sclar, David Alexander
    Robison, Linda M.
    Oganov, Ambartsum M.
    Schmidt, Jennifer M.
    Bowan, Kurt A.
    Castillo, Leigh V.
    CLINICAL DRUG INVESTIGATION, 2013, 33 (03) : 229 - 229
  • [8] Costs of nosocomial Clostridium difficile-associated diarrhoea
    Vonberg, R. -P.
    Reichardt, C.
    Behnke, M.
    Schwab, F.
    Zindler, S.
    Gastmeier, P.
    JOURNAL OF HOSPITAL INFECTION, 2008, 70 (01) : 15 - 20
  • [9] Fidaxomicin in the Treatment of Clostridium difficile-Associated Diarrhoea
    James Greig
    Clinical Drug Investigation, 2013, 33 : 93 - 94
  • [10] Clarithromycin and risk of Clostridium difficile-associated diarrhoea
    Wilcox, MH
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (03) : 358 - 359